Active Ingredient(s): Vorinostat
FDA Approved: * October 6, 2006
Pharm Company: * MERCK
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zolinza Overview

Vorinostat (rINN)[3] also known as suberanilohydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities. Vorinostat is marketed under the name Zolinza (/zolnz/ zoh-LIN-z) by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persi...

Read more Zolinza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Vorinostat

Recent Zolinza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zolinza: (1 result)

Sorted by National Drug Code
  • 0006-0568 Zolinza 100 mg Oral Capsule by Merck Sharp & Dohme Corp.

Other drugs which contain Vorinostat or a similar ingredient: (1 result)